Mazor Robotics Ltd. (NASDAQ:MZOR) traded down NaN during trading on Wednesday . The company traded as low as $59.76 and last traded at $0.00. 1,457,235 shares were traded during trading, an increase of Infinity from the average session volume of 0 shares.

A number of equities research analysts have commented on the company. Ladenburg Thalmann Financial Services set a $67.00 price objective on Mazor Robotics and gave the stock a “buy” rating in a research report on Monday. Barclays PLC lowered Mazor Robotics from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $55.00 to $34.00 in a report on Thursday, October 19th. Zacks Investment Research lowered Mazor Robotics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics in a report on Wednesday, August 30th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $39.83.

Mazor Robotics (NASDAQ:MZOR) last issued its quarterly earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The firm had revenue of $15.46 million during the quarter, compared to analysts’ expectations of $15.38 million. During the same period in the prior year, the firm posted ($0.09) earnings per share. The business’s quarterly revenue was up 86.7% compared to the same quarter last year.

A number of large investors have recently added to or reduced their stakes in MZOR. Quantbot Technologies LP bought a new stake in Mazor Robotics in the second quarter valued at approximately $135,000. JPMorgan Chase & Co. raised its stake in Mazor Robotics by 398.5% in the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after buying an additional 5,579 shares during the period. BB&T Securities LLC bought a new stake in Mazor Robotics in the second quarter valued at approximately $248,000. Dimensional Fund Advisors LP raised its stake in Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 641 shares during the period. Finally, ProVise Management Group LLC bought a new stake in Mazor Robotics in the second quarter valued at approximately $422,000. Hedge funds and other institutional investors own 25.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://theolympiareport.com/2017/11/02/mazor-robotics-ltd-mzor-trading-down-nan.html.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.